SGHT Stock Overview
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$14.88|
|52 Week High||US$42.57|
|52 Week Low||US$14.10|
|1 Month Change||-17.33%|
|3 Month Change||-42.68%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-55.58%|
Recent News & Updates
Sight Sciences: Appeal Is Visually Increasing
Sight Sciences has seen its shares been cut in half compared to the first price after the IPO this past summer. This pullback came while top line sales developments have been solid and another FDA clearance has rolled in. Given this nice setup, I see appeal clearly increasing here.
|SGHT||US Medical Equipment||US Market|
Return vs Industry: Insufficient data to determine how SGHT performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how SGHT performed against the US Market.
|SGHT Average Weekly Movement||10.4%|
|Medical Equipment Industry Average Movement||8.2%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: SGHT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: SGHT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company’s products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States.
Sight Sciences Fundamentals Summary
|SGHT fundamental statistics|
Is SGHT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SGHT income statement (TTM)|
|Cost of Revenue||US$9.04m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.19|
|Net Profit Margin||-129.74%|
How did SGHT perform over the long term?See historical performance and comparison
Is Sight Sciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SGHT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SGHT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SGHT is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: SGHT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SGHT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SGHT is good value based on its PB Ratio (2.9x) compared to the US Medical Equipment industry average (3.5x).
How is Sight Sciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SGHT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SGHT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SGHT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SGHT's revenue (48.3% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: SGHT's revenue (48.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SGHT is forecast to be unprofitable in 3 years.
How has Sight Sciences performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: SGHT is currently unprofitable.
Growing Profit Margin: SGHT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if SGHT's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare SGHT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SGHT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).
Return on Equity
High ROE: SGHT has a negative Return on Equity (-22.82%), as it is currently unprofitable.
How is Sight Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: SGHT's short term assets ($287.8M) exceed its short term liabilities ($10.3M).
Long Term Liabilities: SGHT's short term assets ($287.8M) exceed its long term liabilities ($34.8M).
Debt to Equity History and Analysis
Debt Level: SGHT has more cash than its total debt.
Reducing Debt: Insufficient data to determine if SGHT's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SGHT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SGHT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 34.4% each year
What is Sight Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SGHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SGHT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SGHT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SGHT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SGHT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Badawi (46 yo)
Mr. Paul Badawi is a Co-Founder of Sight Sciences, Inc. since 2011 and serves as its President and Chief Executive Officer since 2011. Mr. Badawi specializes in medical technology investments for 3i. His p...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD496.71K) is below average for companies of similar size in the US market ($USD2.39M).
Compensation vs Earnings: Insufficient data to compare Paul's compensation with company performance.
Experienced Management: SGHT's management team is considered experienced (4.1 years average tenure).
Experienced Board: SGHT's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SGHT insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: SGHT only recently listed within the past 12 months.
Sight Sciences, Inc.'s employee growth, exchange listings and data sources
- Name: Sight Sciences, Inc.
- Ticker: SGHT
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$703.935m
- Shares outstanding: 47.31m
- Website: https://www.sightsciences.com
Number of Employees
- Sight Sciences, Inc.
- 4040 Campbell Avenue
- Suite 100
- Menlo Park
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/19 23:47|
|End of Day Share Price||2022/01/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.